Résumé
Objective:To explore the effect of high fat and low sugar enteral nutrition support on ventilatory function and immune function in patients with chronic obstructive pulmonary disease(COPD) undergoing mechanical ventilation.Methods:From January 2018 to December 2019, 96 COPD patients treated in Zhuji People's Hospital were divided into observation group and control group by simple random sampling method, with 48 cases in each group.The control group was treated with traditional nutrient solution, and the observation group was given high fat and low sugar enteral nutrition.The blood gas analysis, respiratory function, immune function, weaning time and weaning success rate were observed before and after treatment.Results:After treatment, the arterial oxygen partial pressure(PaO 2)[(10.08±0.49)kPa], the blood oxygen saturation (SpO 2)[(96.46±2.15)%] in the observation group were higher than those in the control group[(9.53±0.46)kPa, (95.04±2.08)%]( t=5.670, 3.289, all P<0.05), and the carbon dioxide partial pressure (PaCO 2) [(6.42±0.27)kPa] was lower than that in the control group [(7.33±0.25)kPa]( t=17.134, P<0.05). After treatment, the forced vital capacity(FVC) [(3.03±0.52)L], forced expiratory volume in one second(FEV 1)[(1.61±0.33)L], peak expiratory flow(PEF)(0.54±0.08) in the observation group were higher than those in the control group [(2.78±0.45)L, (1.42±0.31)L, (0.49±0.07)]( t=2.519, 2.907, 3.259, all P<0.05). The immunoglobulin G [(12.45±1.32)g/L], immunoglobulin M [(1.88±0.34)g/L] and immunoglobulin A [(2.68±0.47)g/L] in the observation group were higher than those in the control group [(11.66±1.28)g/L, (1.65±0.37)g/L, (2.38±0.45)g/L] ( t=2.977, 3.171, 3.194, all P<0.05). The weaning time of the observation group was (6.94±1.55)d, which was lower than that of the control group [(8.73±1.41)d] ( t=5.919, P<0.05). The success rate of weaning of the observation group (91.67%) was higher than that of the control group (72.92%) (χ 2=5.790, P<0.05). Conclusion:High fat and low sugar enteral nutrition support can improve the ventilation indicators and immune function indicators of COPD patients with mechanical ventilation, shorten the time of mechanical ventilation, and improve the success rate of weaning.
Résumé
Objective Studies show that the ERCC1 gene may be involved in secondary cisplatin resistance.This article aims to investigate the effects of shRNA targeting silencing excision repair cross-complementation group 1 (ERCC1-shRNA) on the proliferation and apoptosis of lung cancer A549/DDP cells treated with different concentrations of cisplatin.Methods Lung cancer A549/DDP cells were divided into a negative control, a blank control, an ERCC1-shRNA1, and an ERCC1-shRNA2 group.Human interfering RNA (RNAi) targeting the human ERCC1 gene was constructed and transfected into the A549/DDP cells using Lipofectamine 2000.The mRNA and protein expressions of ERCC1 in the A549/DDP cells were detected by real-time PCR and Western blot respectively, the proliferation-inhibition rate was assessed by MTT, and their cell cycle and apoptosis were determined by flow cytometry.Results ERCC1-shRNA was successfully constructed and transfected into the A549/DDP cells.Both the mRNA and protein expressions of ERCC1 were significantly lower in the ERCC1-shRNA1 (0.20±0.04 and 0.24±0.10) and ERCC1-shRNA2 (0.47±0.28 and 0.37±0.11) than in the negative control (0.96±0.12 and 1.32±0.13) and blank control groups (0.84±0.07 and 1.45±0.23) (P<0.01).Compared with the negative and blank control groups, the ERCC1-shRNA1 group showed a significantly decreased IC50 value (16.71±2.33 and 16.69±1.69 vs 7.78±0.54, P<0.01) and an increased proportion of G0/G1 phase cells ([72.87±3.23] and [71.75±4.56] vs [82.99±4.23]%, P<0.05), with the cell cycle arrested in the G0/G1 phase.The apoptosis rate of the cells in the ERCC1-shRNA1 group was remarkably lower after treated with cisplatin at the concentrations of 6.25 and 12.5 μg/mL than at 0 μg/mL ([8.17±0.65] and [11.91±1.41] vs [29.97±3.14]%, P<0.05).Conclusion ERCC1-shRNA can inhibit the proliferation and enhance the apoptosis of A549/DDP cells by silencing the expression of the ERCC1 gene.
Résumé
AIM: To evaluate the therapeutic effect and safety of the rifamycin sodium injection (SV) in treatment of patients with pulmonary tuberculosis. METHODS: 44 cases of pulmonary tuberculosis were randomly allocated to two groups: rifamycin sodium group and routine treatment group. Chemotherapy regimens: in the rifamycin sodium group, 21 cases were treated with the regimen of 2HZE+SV/7HR; and in the routine treatment group, 23 cases were treated with the regimen of 2HRZE/7HR. RESULTS: The sputum negative conversion rate of the rifamycin sodium group was 85.7 %, and the foci vanishing rate was 90.5 %, while the both rates in the routine treatment group were 60.9 % and 60.9 %, respectively. There was significant difference between the two groups (P